After screening 50,000 compounds using a high-through-put assay, Dr. Alan S. Verkman and associates have identified a thiazolidinone inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that could help uncover the pathophysiologic mechanisms of cystic fibrosis.
In addition, the researchers suggest in the December issue of The Journal of Clinical Investigation, that the CFTR inhibitor has potential clinical applications in the treatment of secretory diarrheas and cystic kidney disease.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!